ESMO 2022 | Lung cancer highlights from ESMO 2022

Alessandra Bearz, MD, CRO National Cancer Institute, Aviano, Italy, highlights key updates in lung cancer from the European Society for Medical Oncology (ESMO) 2022 annual meeting, including the optimal duration of chemo-immunotherapy in early and metastatic settings. Dr Bearz also touches on a plenary symposium presentation elucidating the role of pollution in the development of EGFR-mutant non-small cell lung cancer in non-smoker populations. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.